Inhibrx Biosciences Files 8-K

Ticker: INBX · Form: 8-K · Filed: Oct 23, 2025 · CIK: 2007919

Inhibrx Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyInhibrx Biosciences, Inc. (INBX)
Form Type8-K
Filed DateOct 23, 2025
Risk Levellow
Pages6
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 8-k, disclosure

TL;DR

Inhibrx filed an 8-K on 10/23/25, likely containing important company updates.

AI Summary

On October 23, 2025, Inhibrx Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing indicates Inhibrx Biosciences, Inc. is providing updates or disclosures as required by the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard SEC filing notification without specific negative or positive material events disclosed.

Key Players & Entities

  • Inhibrx Biosciences, Inc. (company) — Registrant
  • October 23, 2025 (date) — Date of Report
  • Delaware (jurisdiction) — State of Incorporation
  • 11025 N. Torrey Pines Road, Suite 140 (address) — Principal Executive Offices
  • La Jolla, CA (location) — Principal Executive Offices City/State

FAQ

What is the primary purpose of this 8-K filing by Inhibrx Biosciences, Inc.?

The filing is for Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, as of October 23, 2025.

When was this 8-K report filed?

The report was filed on October 23, 2025.

What is the principal executive office address for Inhibrx Biosciences, Inc.?

The principal executive offices are located at 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA 92037.

What is the state of incorporation for Inhibrx Biosciences, Inc.?

Inhibrx Biosciences, Inc. is incorporated in Delaware.

What is the IRS Employer Identification Number for Inhibrx Biosciences, Inc.?

The IRS Employer Identification Number is 99-0613523.

Filing Stats: 1,846 words · 7 min read · ~6 pages · Grade level 14 · Accepted 2025-10-23 16:05:56

Key Financial Figures

  • $0.0001 — ich registered Common Stock, par value $0.0001 per share INBX The Nasdaq Global Market

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 23, 2025, Inhibrx Biosciences, Inc. ("Inhibrx") issued a press release announcing (i) positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and (ii) updates on its colorectal cancer and Ewing sarcoma expansion cohorts, as discussed in Item 8.01 of this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On October 23, 2025, Inhibrx posted an updated copy of its corporate presentation to the "Investors" tab of its website at www.inhibrx.com. The presentation is attached to this Current Report on Form 8-K as Exhibit 99.2. Inhibrx from time to time presents and/or distributes the presentation to the investment community during conferences and meetings to provide updates and summaries of its business. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Other Events

Item 8.01. Other Events. On October 23, 2025, Inhibrx announced (i) positive topline results from its registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma and (ii) updates on the ongoing expansion cohorts investigating ozekibart in combination with FOLFIRI in late-line colorectal cancer and in combination with irinotecan and temozolomide in refractory Ewing sarcoma. Inhibrx also announced that it plans to submit to the U.S. Food and Drug Administration a biologics license application in the second quarter of 2026. Chondrosarcoma The ChonDRAgon study met its primary endpoint of a statistically significant and clinically meaningful median progression-free survival ("PFS") for patients with advanced or metastatic chondrosarcoma treated with ozekibart compared to placebo. Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo (stratified Hazard Ratio [HR] 0.479; 95% CI: 0.33, 0.68); P<0.0001), more than doubling median PFS to 5.52 months versus 2.66 months for placebo. Importantly, ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma, a disease with no approved systemic options. The benefit of ozekibart was consistent across all pre-specified subgroups, including patients with isocitrate dehydrogenase ("IDH")-wild-type and IDH-mutant tumors. Other key secondary endpoints, including disease control rate (54% vs 27.5%), and delay to deterioration in pain and physical function, further supported the clinical benefit observed with ozekibart. Ozekibart was generally well tolerated, with a manageable safety profile. The most common treatment-related adverse events were fatigue, constipation, and nausea. Hepatotoxicity, a known risk for this mechanism of action, occurs during the first treatment cycle and is in patients with under

Forward-Looking Statements

Forward-Looking Statements Inhibrx cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx's judgments and beliefs regarding the strength of Inhibrx's pipeline; statements regarding the safety and efficacy of its therapeutic candidate, ozekibart, based on topline and interim results; the potential for ozekibart to be used for the treatment of CRC, Ewing sarcoma and solid tumor indications; the clinical development of ozekibart, including expected enrollment in the expansion cohort, data readouts, regulatory submissions and interactions, and the timing thereof; and any presumption that topline, interim or preliminary data will be representative of final data or data in later clinical trials. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: topline data may not accurately reflect the complete results of a particular study or trial and remain subject to audit, and final data may differ materially from topline data; the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of topline, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; results from preclinical studies or early clinical trials not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of its therapeutic candidates that may limit their development, regulatory approval and/or commercialization; the potential

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press Release issued by Inhibrx Biosciences, Inc. on October 23, 2025 99.2 Corporate Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 23, 2025 INHIBRX BIOSCIENCES, INC. By: /s/ Kelly Deck Name: Kelly Deck Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.